drugset / Trial / NCT00754312
A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer
Non-randomizedParallel-groupOpen-labelOther
Summary
The primary objective of the study is to evaluate changes in the expression of targeted biomarkers in invasive breast cancer tissue before and after SNDX-275 administration.
Timeline
- Start
- 2008-06
- Primary completion
- 2009-02-28
- Completion
- 2009-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entinostat | Small molecule | — | — |